John Stagg
17PUBLICATIONS
150CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (17)
Sort by Publication Date:
|Apr 03, 2026
Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy.Samya Aouad, Maleck Kadiri, David Allard
|Feb 19, 2026
The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver β-catenin in colorectal cancer.Mariana Acevedo, Florence Dô, Firas El-Mortada
|Dec 09, 2024
Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis.David Allard, Jeanne Cormery, Salma Bricha
|Dec 12, 2023
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.Laurence Buisseret, Delphine Loirat, Philippe Aftimos
|Nov 03, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.Laurence Buisseret, Delphine Loirat, Philippe Aftimos
|Jul 07, 2023
The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy.John Stagg, Encouse Golden, Erik Wennerberg
Pageof 3
Frequent Collaborators
4 joint publications
Laurence Buisseret
3 joint publications
Simon Turcotte
2 joint publications
Kevin Punie
2 joint publications
David Allard
2 joint publications
Isabelle Cousineau
2 joint publications
Christian Maurer
2 joint publications
Ricard Masia
2 joint publications
Benjamin Haibe-Kains
2 joint publications
Célia Jacoberger-Foissac
2 joint publications
LeeAnn Ramsay
